FOPH

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

Retrieved on: 
Mittwoch, November 1, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Grand duchy, Food, Face, VWS, Disease, Gonorrhea, MHLW, Partnership, The Lancet, National Rural Development Partnership, Infection, Nursing care plan, Reproduction, SAMRC, Azithromycin, Hope, Physician, Prevalence, HIV, Ceftriaxone, BMBF, Neisseria gonorrhoeae, University, Therapy, Patient, Food and Drug Administration, Infertility, DFID, Heart, BMG, NIAID, MD, DHSC, AMR, BZ, Clinical trial, World Health Organization, Zoliflodacin, Woman, Multidrug-resistant bacteria, FOPH, South African Medical Research Council, Death, Ministry, Pharmaceutical industry, Vaccine, Medicine

These positive preliminary findings offer hope for patients with this condition, particularly in the face of rising antibiotic resistance to current regimens.

Key Points: 
  • These positive preliminary findings offer hope for patients with this condition, particularly in the face of rising antibiotic resistance to current regimens.
  • It also paves the way for a new research and development model in the global fight against antimicrobial resistance (AMR).
  • Now, the positive results of this landmark Phase 3 trial confirm that zoliflodacin has the potential to tackle the most difficult-to-treat gonorrhea infections.
  • This builds on the critical Phase 2 clinical trial sponsored by the U.S. National Institute of Allergy and Infectious Diseases (NIAID).

Kinarus Therapeutics Group Reports 2022 Annual Results

Retrieved on: 
Mittwoch, Mai 31, 2023
Insurance, Maintenance, Therapy, File, D&O, Hangzhou, AMD, Annual, COVID-19, Tax, Federal Office of Public Health, FOPH, Federal, IP, KNRS, Consultant, Reverse takeover, Public health, Companion dog, Patient, Annual report, Research, IPF, CHF, Idiopathic pulmonary fibrosis, Pharmaceutical industry, Cryptocurrency, Muthiri kinaru

Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today published the Annual Report with full year audited consolidated financial results for the year ended 31 December 2022.

Key Points: 
  • Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today published the Annual Report with full year audited consolidated financial results for the year ended 31 December 2022.
  • The reporting of audited financial results follows the announcement of the unaudited key financial figures published on 5 May 2023.
  • On 28 April 2023, Kinarus announced that the SIX Exchange Regulation ("SER") approved a deadline extension until the end of May 2023 for the publication of the Kinarus’ 2022 annual report and asked Kinarus to report unaudited key financial figures for the year ended 31 December 2022.
  • To this end, Kinarus engaged Great Health Companion Group Ltd., to explore financing and partnering options for KIN001 in China.

Geneuro Receives CHF 6.7 Million (EUR 6.4 Million) in Funding From the Swiss Government for the Development of Temelimab Against Long-COVID

Retrieved on: 
Montag, Dezember 13, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Clinical Trials, Other Health, Forward-looking statement, HERV-W, COVID, Technology, Symptoms of COVID-19, Company, FOPH, HIV disease progression rates, Severe acute respiratory syndrome coronavirus 2, Clinical trial, Euronext Paris, Genome, Brain, Public health, Association, Degenerative disease, Industry, Multiple sclerosis, COVID-19, Lancet, Rufus Herve Bacote, CEO, Swiss Federal Institute of Aquatic Science and Technology, Patient, Lymphocyte, Endothelium, Patent, Neurodegeneration, Alzheimer's disease, Blood, Long COVID, Pediatric acute-onset neuropsychiatric syndrome, Parkinson's disease, Lists of diseases, Pharmaceutical industry, Vaccine, Medical imaging, W-ENV and COVID-19, GeNeuro, W-ENV AND COVID-19, GENEURO

"We are extremely grateful for this funding from the FOPH, which will allow us to test GeNeuro's treatment for the neuropsychiatric forms of Long-COVID," said Jess Martin-Garcia, CEO of GeNeuro.

Key Points: 
  • "We are extremely grateful for this funding from the FOPH, which will allow us to test GeNeuro's treatment for the neuropsychiatric forms of Long-COVID," said Jess Martin-Garcia, CEO of GeNeuro.
  • Our approach is one of the first concrete leads to explain these problems, and also potentially to treat them with temelimab, GeNeuro's anti-W-ENV antibody."
  • This may allow early identification and treatment of patients who could benefit from anti-W-ENV therapy with temelimab.
  • Based in Geneva, Switzerland, and with an R&D center in Lyon, France, GeNeuro holds the rights to 17 patent families that protect its technology.

Memo Therapeutics AG to Receive CHF 10.5 Million from Swiss Federal Funding Programme to Clinically Develop SARS-CoV-2 Antibody Against COVID-19

Retrieved on: 
Montag, Dezember 13, 2021
Health, Infectious Diseases, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Therapy, FOPH, Severe acute respiratory syndrome coronavirus 2, Neutralizing antibody, COVID-19, Inhalation, Infection, Efficiency, Mining, Public health, Antibody, Vaccine, Pharmaceutical industry

Memo Therapeutics AG , an innovator in the field of antibody discovery and development, announced today the receipt of CHF10.5 million from the Swiss Federal Funding Programme for COVID-19 Medicines to clinically develop COVAB 36, a potent, fully-human monoclonal antibody for the treatment of SARS-CoV-2 infections.

Key Points: 
  • Memo Therapeutics AG , an innovator in the field of antibody discovery and development, announced today the receipt of CHF10.5 million from the Swiss Federal Funding Programme for COVID-19 Medicines to clinically develop COVAB 36, a potent, fully-human monoclonal antibody for the treatment of SARS-CoV-2 infections.
  • The Swiss Governments support in advancing clinical development of our SARS-CoV-2 antibody is an important milestone as we rapidly build upon our excellent preclinical data, said Karsten Fischer, Chief Executive Officer of Memo Therapeutics AG.
  • The Swiss Federal Funding Programme for COVID-19 Medicines was implemented by Swiss Federal Office of Public Health (FOPH) with support of Innosuisse.
  • Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis.